Aripiprazole, Aripiprazole Monohydrate, and Aripiprazole Lauroxil

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.019

16 - Aripiprazole, Aripiprazole Monohydrate, and Aripiprazole Lauroxil

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

Aripiprazole has been available since 2002, with long-acting injectable versions approved in 2013 and 2015. Aside from clozapine, all antipsychotics approved prior to aripiprazole acted principally via postsynaptic dopamine D2 receptor antagonism in the associative striatum [2, 3]. While D2 antagonist antipsychotics are very useful, excessively high levels of striatal D2 occupancy (i.e. >> 80% reduction in the postsynaptic dopamine signal) resulted in higher rates of adverse neurological effects (e.g. parkinsonism, akathisia), subjective complaints of dysphoria or decreased well-being, and occasionally symptomatic worsening [4, 5].

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 318 - 336

DOI: https://doi.org/10.1017/9781009002103.019 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Sparshatt, A., Taylor, D., Patel, M. X., et al. (2010). A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry, 71, 1447–1556.Google Scholar

Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., et al. (2010). Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry, 67, 231–239.Google Scholar

Kim, J. H., Son, Y. D., Kim, H. K., et al. (2011). Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride. J Clin Psychopharmacol, 31, 507–511.Google Scholar

Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry, 149, 500–505.Google Scholar

Veselinovicć, T., Scharpenberg, M., Heinze, M., et al. (2019). Dopamine D2 receptor occupancy estimated from plasma concentrations of four different antipsychotics and the subjective experience of physical and mental well-being in schizophrenia: results from the randomized NeSSy Trial. J Clin Psychopharmacol, 39, 550–560.Google Scholar

Burris, K. D., Molski, T. F., Xu, C., et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther, 302, 381–389.Google Scholar

Tadori, Y., Forbes, R. A., McQuade, R. D., et al. (2011). In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol, 668, 355–365.Google Scholar

Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar

Takeuchi, H. and Remington, G. (2013). A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology (Berl), 228, 175–185.Google Scholar

Kane, J. M., Correll, C. U., Goff, D. C., et al. (2009). A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry, 70, 1348–1357.Google Scholar

Cipriani, A., Accordini, S., Nose, M., et al. (2013). Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. J Clin Psychopharmacol, 33, 533–537.Google Scholar

Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.Google Scholar

Girgis, R. R., Slifstein, M., D’Souza, D., et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl), 233, 3503–3512.Google Scholar

Stahl, S. M. (2017). Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr, 22, 375–384.Google Scholar

Stroup, T. S., McEvoy, J. P., Ring, K. D., et al. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry, 168, 947–956.Google Scholar

Kirschbaum, K. M., Müller, M. J., Malevani, J., et al. (2008). Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry, 9, 212–218.Google Scholar

Lin, S. K., Chen, C. K., and Liu, Y. L. (2011). Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. J Clin Psychopharmacol, 31, 758–762.Google Scholar

Yokoi, F., Grunder, G., Biziere, K., et al. (2002). Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology, 27, 248–259.Google Scholar

Mamo, D., Graff, A., Mizrahi, R., et al. (2007). Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry, 164, 1411–1417.Google Scholar

Grunder, G., Fellows, C., Janouschek, H., et al. (2008). Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry, 165, 988–995.Google Scholar

Kegeles, L. S., Slifstein, M., Frankle, W. G., et al. (2008). Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology, 33, 3111–3125.Google Scholar

Mizrahi, R., Mamo, D., Rusjan, P., et al. (2009). The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol, 12, 715–721.Google Scholar

Takahata, K., Ito, H., Takano, H., et al. (2012). Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [C]raclopride and [C]FLB457. Psychopharmacology, 222, 165–172.Google Scholar

Kurose, S., Mimura, Y., Uchida, H., et al. (2020). Dissociation in pharmacokinetic attenuation between central dopamine D2 receptor occupancy and peripheral blood concentration of antipsychotics: a systematic review. J Clin Psychiatry, 81, 19r13113.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar

Otsuka America Pharmaceutical Inc. (2020). Abilify package insert. Rockville, MD.Google Scholar

Nemoto, K., Mihara, K., Nakamura, A., et al. (2012). Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit, 34, 188–192.Google Scholar

Suzuki, T., Mihara, K., Nakamura, A., et al. (2014). Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit, 36, 651–655.Google Scholar

Meyer, J. M. (2017). Converting oral to long acting injectable antipsychotics: a guide for the perplexed. CNS Spectr, 22, 14–28.Google Scholar

Otsuka America Pharmaceutical Inc. (2020). Abilify Maintena package insert. Rockville, MD.Google Scholar

Alkermes Inc. (2020). Aristada package insert. Walltham, MA.Google Scholar

Alkermes Inc. (2020). Aristada Initio package insert. Walltham, MA.Google Scholar

Hard, M. L., Mills, R. J., Sadler, B. M., et al. (2017). Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol, 37, 289–295.Google Scholar

Hard, M. L., Mills, R. J., Sadler, B. M., et al. (2017). Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs, 31, 617–624.Google Scholar

Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.Google Scholar

Jain, R., Meyer, J. M., Wehr, A. Y., et al. (2020). Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS Spectr, 25, 323–330.Google Scholar

Meltzer, H. Y., Risinger, R., Nasrallah, H. A., et al. (2015). A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry, 76, 1085–1090.Google Scholar

Potkin, S. G., Saha, A. R., Kujawa, M. J., et al. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry, 60, 681–690.Google Scholar

Saha, A., Ali, M. W., lngenito, G. G., et al. (2002). P.4.E.026 – Safety and tolerability of aripiprazole at doses higher than 30 mg (abstract from the XXIII CINP Congress, Montréal, June 23–27, 2002). Int J Neuropsychopharmacol, 5, S185.Google Scholar

Christensen, A. P., Boegevig, S., Christensen, M. B., et al. (2018). Overdoses with aripiprazole: signs, symptoms and outcome in 239 exposures reported to the Danish Poison Information Centre. Basic Clin Pharmacol Toxicol, 122, 293–298.Google Scholar

Chavez, B. and Poveda, R. A. (2006). Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances. Ann Pharmacother, 40, 2265–2268.Google Scholar